The American college edifice [i]or[...

The American college edifice [i]or[/i] building of Obstetricians and Gynecologists (ACOG) has released guidelines upon the clinical management of women with human papillomavirus (HPV) infection. ACOG Practice Bulletin No. 61 was published in the April 2005 issue of Obstetrics and Gynecology

HPV infection can be diagnosed clinically (genital warts), cytologically (Papanicolaou smear), or virologically (DNA testing). The more austere abnormalities attributed to HPV infection correspond to the traditional classification of precursor lesions of invasive cervical cancer: mild, moderate, or hard cervical intraepithelial neoplasia (CIN, which includes low-grade and high-grade squamous intraepithelial lesions [LSIL and HSIL, respectively]). Each year in the United States, up to 3 million women are diagnosed with atypical squamous enclosed spaces of undetermined significance (ASCUS) and more than 1 million women are diagnosed with LSIL. inferences of a 2001 study through the National Cancer Institute showed that 83 percent of women with LSIL proofed positive for high-risk HPV DNA. in the greatest degree cervical HPV infections diagnosed according to polymerase chain reaction and other nucleic acid detection orderly dispositions seem to be transient. However, older patient age and high-risk HPV protoplasts are associated with infections of longer duration.

Treatment for genital warts should be guided by way of patient preference and physician experience. Because of a similar risk of return no single treatment for external genital warts can be commended over other treatments. Visible genital warts frequently resolve spontaneously. Warts that are small in size and scarcely any in number will respond to almost any treatment or to no treatment at all. Warts upon moist or mucosal surfaces generally are more responsive to topical treatments compared with warts forward dry surfaces. Warts that do not suit to a particular treatment after three physician-administered treatments, and warts that are not cleared completely after six treatments, should be reevaluated. Pregnant women should not use patient-applied topical treatments.

Although evidence that condoms tender complete protection from HPV infection is lacking, condom use may lessen the risk of HPV-related disease like as genital warts and cervical neoplasia. Condom use may be effective in the clearance of HPV and HPV-related lesions.

A combination of cervical cytology and HPV DNA testing is appropriate in women 30 years and older If this combination is used, women with negative inferences on both tests should be rescreen no more than each three years. Women older than 30 years with negative cytology who experiment positive for high-risk HPV DNA should repeat the two tests in six to 12 month Patients with persistent high-risk HPV should go through colposcopy regardless of the cytology result

Studies using combined HPV DNA testing and cervical cytology have a 99 to 100 percent negative predictive value for CIN grades 2 and 3; women with negative conjoined test results can be reassured that their risk of unidentified CIN grades 2 and 3 and of cervical cancer, is approximately sole one in 1,000. HPV DNA testing is not commended in women with LSIL, atypical squamous confined apartments that cannot exclude HSIL, or atypical glandular small rooms Women with high-risk HPV symbols who have ASCUS or LSIL, further who are not found to have CIN grade 2 or 3 at their initial colposcopy have an approximately 10 percent risk of developing CIN grade 2 or 3 within brace years.

HPV DNA testing could be used as a trial of cure in women with CIN grade 2 or 3 at six to 12 month after excision or ablation of the transformation clime Women with high-risk HPV should be referr for colposcopy

COPYRIGHT 2005 American Academy of Family Physicians

COPYRIGHT 2005 Gale Group